# US 2010/0167313 A1 · Anti-idiotype antibody against an antibody against the amyloid beta peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0167313 A1
- Document ID: US20100167313A1
- Status: Published application
- Kind: A1
- Application number: 12/637,833
- Filed: 2009-12-15
- Published: 2010-07-01
- Earliest claimed: 2008-12-22
- Assignees: Hoffmann-La Roche Inc.
- Inventors: ULRICH ESSIG; WOLFGANG HOESEL; KAY-GUNNAR STUBENRAUCH; RUDOLF VOGEL
- Web page: https://patentgrep.com/patent/US20100167313A1

## CPC

- G01N 33/686: {Anti-idiotype}
- C07K 16/4241: {against anti-human or anti-animal Ig}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention is directed to an anti-idiotype antibody binding to the complementary determining region of an antibody against the amyloid β peptide. In one embodiment said antibody binds to the same epitope or an overlapping epitope as the antibody obtainable from the cell line DSM ACC2939. Also reported is an immunoassay for the determination of an antibody against the amyloid β peptide and for determination of an anti-idiotype antibody binding to an antibody against the amyloid β peptide.

## Claims

### Claim 1

An antibody that binds to a complementary determining region of an antibody against the amyloid β peptide and binds to the same epitope, or an overlapping epitope, as the antibody obtained from the cell line DSM ACC2939.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the heavy chain variable domain of the antibody against the amyloid β peptide comprises a CDR3 with an amino acid sequence selected from SEQ ID NO: 1, 2, and 3 and the light chain variable domain of said antibody against the amyloid β peptide comprises a CDR3 with an amino acid sequence selected from SEQ ID NO: 4, 5, and 6.

### Claim 3

An antibody derived from the cell line DSM ACC2939.

### Claim 4

A method for the immunological determination of an antibody against the amyloid β peptide in a sample comprising an immunoassay employing an antibody obtained from cell line DSM ACC2939.

### Claim 5 (depends on 4)

The method of claim 4, wherein the immunoassay comprises a capture antibody, a tracer antibody and a detection antibody, wherein said capture antibody is a biotinylated anti-idiotype antibody against an antibody against the amyloid β peptide obtained from cell line DSM ACC2939 conjugated to a solid phase via streptavidin, said tracer antibody is an anti-idiotype antibody against an antibody against the amyloid β peptide obtained from cell line DSM ACC2939 conjugated to digoxygenin as detectable label, and said detection antibody is an antibody against digoxygenin conjugated to a peroxidase.

### Claim 6 (depends on 4)

The method of claim 4, wherein the immunoassay comprises the amyloid β peptide conjugated to a solid phase, an anti-idiotype antibody against an antibody against the amyloid β peptide obtained from cell line DSM ACC2939 conjugated to digoxygenin as detectable label, and a detection antibody against digoxygenin conjugated to a peroxidase.

### Claim 7 (depends on 4)

The method of claim 4, wherein the immunoassay comprises a capture antibody and a tracer antibody, wherein said capture antibody is a mixture comprising at least two of said antibodies that differ in the antibody site at which they are conjugated to the solid phase, and the tracer antibody is a mixture of said antibody comprising at least two of said antibodies that differ in the antibody site at which they are conjugated to the detectable label.

### Claim 8

A method for the immunological determination of an anti-idiotype antibody against an antibody against the amyloid β peptide in a sample comprising an immunoassay employing an antibody obtained from cell line DSM ACC2939.

### Claim 9 (depends on 8)

The method of claim 8, wherein the immunoassay comprises a capture antibody and a tracer antibody, wherein said capture antibody is an antibody against the amyloid β peptide conjugated to a first part of a binding pair and said tracer antibody is an antibody against the amyloid β peptide conjugated to a detectable label.

### Claim 10 (depends on 8)

The method of claim 8, wherein the immunoassay comprises the amyloid β peptide conjugated to a solid phase, an antibody against the amyloid β peptide conjugated to digoxygenin as detectable label, and a detection antibody against digoxygenin conjugated to a peroxidase.

### Claim 11 (depends on 8)

The method of claim 8, wherein the immunoassay comprises a capture antibody and a tracer antibody, wherein said capture antibody is a mixture comprising at least two of said antibodies that differ in the antibody site at which they are conjugated to the solid phase, and the tracer antibody is a mixture of said antibody comprising at least two of said antibodies that differ in the antibody site at which they are conjugated to the detectable label.
